Abstracts Archive - Page 1594 of 2607 - ACR Meeting Abstracts

Abstract Number: 113 • 2017 Pediatric Rheumatology Symposium
Exploring the role of pediatric rheumatologists in the diagnosis and management of autoimmune encephalitis
Eyal Muscal¹, Heather Van Mater², Tania Cellucci³, Dominic Co⁴, Jennifer Frankovich⁵, Marisa S. Klein-Gitelman⁶, Marinka Twilt⁷ and Susanne Benseler⁸, ¹Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Pediatrics/ Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ³McMaster University, hamilton, ON, Canada, ⁴Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁵Pediatrics, Standford University, Palo Alto, CA, ⁶Div of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/NW University, Chicago, IL, ⁷Paediatrics, University Of Calgary, Calgary, AB, Canada, ⁸Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: Autoimmune encephalitis (AE) encompasses a spectrum of immune-mediated brain disorders that cause severe neuropsychiatric manifestations. These disorders often lead to protracted hospital stays, complex…
Abstract Number: 146 • 2017 Pediatric Rheumatology Symposium
Age-Related Differences in Neuronal High Mobility Group Box-1 and Resolvin D1 Receptors in Collagen-Induced Arthritis
Tracy Wilson-Gerwing and Alan Rosenberg, Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada
Background/Purpose: More thorough understanding of age-related molecular interactions that drive inflammation and inflammatory pain is required to help guide evidenced-based, age appropriate treatment strategies that…
Abstract Number: 67 • 2017 Pediatric Rheumatology Symposium
Relapse and Remission in Children with Chronic Non-Infectious Uveitis Treated with Methotrexate and Tumor Necrosis Factor-α Inhibitors
Courtney McCracken¹, Curtis Travers¹, Kirsten Jenkins², Carolyn Drews-Botsch³, Steven Yeh⁴, Sampath Prahalad^1,5 and Sheila Angeles-Han^6,7, ¹Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁴Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁵Pediatrics, Emory Children's Center, Atlanta, GA, ⁶Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Pediatrics, University of Cincinnati, Cincinnati, OH
Background/Purpose: Methotrexate (MTX) and tumor necrosis factor-α inhibitors (TNFi) are common treatments for children with chronic non-infectious uveitis (NIU). Optimal duration of treatment prior to…
Abstract Number: 92 • 2017 Pediatric Rheumatology Symposium
Mycophenolate Mofetil is an Effective Induction Therapy Agent in Childhood-onset Pure Membranous Lupus Nephritis
Maria Pereira¹, Eyal Muscal², Marietta DeGuzman³, Anna Carmela Sagcal-Gironella⁴ and Scott E. Wenderfer⁵, ¹Immunology, Allergy & Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁵Pediatrics-Renal, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Treatment guidelines for childhood-onset class V membranous lupus nephritis (MLN) have not yet been established. The addition of mycophenolate mofetil (MMF) has shown improvement…
Abstract Number: 153 • 2017 Pediatric Rheumatology Symposium
Training pediatric rheumatology fellows intra-articular injection techniques and skills using a cadaver based musculoskeletal curriculum
Baruch Goldberg¹, Amanda Brown² and Monica Marcus³, ¹Pediatric Rheumatology, Texas Children's Hospital, Houston, TX, ²Allergy, Immunology and Rheumatology, Texas Children's Hospital, houston, TX, ³Pediatric Immunology, Allergy and Rheumatology, Texas Children's Hospital, Houston, TX
Background/Purpose: Intra-articular injections are important to treat children with arthritis. Practice differences, comfort levels, and reimbursement can decrease fellow exposure to this skill. The purpose…
Abstract Number: 50 • 2017 Pediatric Rheumatology Symposium
Tumor necrosis factor-α (TNFα) inhibitor-induced psoriasis in juvenile idiopathic arthritis (JIA) patients
Daniel Groth¹, Sivia Lapidus², Simona Nativ² and Maria Perez³, ¹Goryeb Children's Hospital, Morristown, NJ, ²Pediatric Rheumatology, Goryeb Children's Hospital, Morristown, NJ, ³Pediatric Gastroenterology, Goryeb Children's Hospital, Morristown, NJ
Background/Purpose: Occurrence of psoriasis while on TNFα antagonists is a paradoxical effect of agents that treat psoriasis, and is described in larger cohorts of inflammatory…
Abstract Number: 68 • 2017 Pediatric Rheumatology Symposium
HLA-DRB1 in Non-Hispanic African American Children with Juvenile Idiopathic Arthritis and Chronic Anterior Uveitis
Lai Hin Kimi Chan¹, Courtney McCracken¹, Kirsten Jenkins², Steven Yeh³, Purnima Patel⁴, Sampath Prahalad¹ and Sheila Angeles-Han⁵, ¹Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine, Atlanta, GA, ⁵Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: HLA-DRB1*08, 11 and 13 are strong risk alleles for various juvenile idiopathic arthritis (JIA) subtypes. We reported that carriage of DRB1*11 and *13 increased…
Abstract Number: 104 • 2017 Pediatric Rheumatology Symposium
Rituximab Treatment for Chronic Steroid-Dependent Henoch-Schonlein Purpura
Esraa M. A. Eloseily^1,2, Courtney Crayne¹, Melissa L Mannion³, Saji P Azerf⁴, Peter Weiser¹, Timothy Beukelman¹, Matthew L. Stoll¹, Dan Feig⁵, Prescott Atkinson⁶ and Randy Q. Cron¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Pediatrics, Assiut University, Assiut, Egypt, ³Pediatric rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴School of medicine, Univesity of Alabama at Birmingham,, Birmingham, AL, ⁵Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Allergy and Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Henoch-Schonlein purpura (HSP) is a small vessel vasculitis characterized by non-thrombocytopenic purpura, abdominal pain, arthritis, and glomerulonephritis. Typically, HSP is self-limited, but more severe…
Abstract Number: 48 • 2017 Pediatric Rheumatology Symposium
Methotrexate use and route of administration in JIA: Results from the Childhood Arthritis & Rheumatology Research Alliance Registry
Sarah Ringold¹, Fenglong Xie², Yukiko Kimura³, Laura E. Schanberg⁴, Timothy Beukelman⁵ and and the CARRA Registry Investigators, ¹Seattle Children's Hospital, Seattle, WA, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Hackensack University Medical Center, Hackensack, NJ, ⁴Pediatrics, Duke Medical Center, Durham, NC, ⁵Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry began enrolling children with juvenile idiopathic arthritis (JIA) in July 2015. The large number of…
Abstract Number: 160 • 2017 Pediatric Rheumatology Symposium
Stepping Stones to Transition Smartly
Elizabeth Roth-Wojcicki¹, Jan Lemke², Sarah Thomson³, Sarah Liedtke⁴ and Kristi Cedars², ¹Pediatrics, Medical College of WI, Wauwatosa, WI, ²Rheumatology clinic, Children's Hospital of WI, Milwaukee, WI, ³Pediatric Rheumatology, Children's Hospital of Wisconsin, Milwaukee, WI, ⁴Rheumatology clinic, Children's hospital of WI, Milwaukee, WI
Background/Purpose: Living with a rheumatic disease presents many challenges for adolescents. To help them meet these challenges and become healthy independent adults, teams need to…
Abstract Number: 145 • 2017 Pediatric Rheumatology Symposium
JAK Inhibition Rescues Novel PSMB8 Mutations
J. Brian Shirley¹, Tiphanie Vogel² and Marietta de Guzman³, ¹Allergy, Immunology and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Department of Pediatrics, Division of Immunology, Allergy and Rheumatology and the Center for Human Immunology at Texas Children's Hospital., Baylor College of Medicine, Houston, TX, ³Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: The proteasome associated autoinflammatory syndromes (PRAAS) are characterized by autosomal recessive mutations in the PSMB8 gene. These mutations result in an early childhood overproduction…
Abstract Number: 144 • 2017 Pediatric Rheumatology Symposium
Linear Discriminant Analysis of Cultured Fibroblast-like Synoviocytes Identifies 6 Candidate Genes Which Predict Extended Course in Juvenile Idiopathic Arthritis
AnneMarie Brescia¹, Megan Simonds², Suzanne M. McCahan³, Timothy Bunnell³, Kathleen E. Sullivan⁴ and Carlos D. Rosé⁵, ¹Pediatric Rheumatology, Nemours A.I. duPont Hospital for Children, Wilmington, DE, ²Nemours, Nemours Biomedical Research, Wilmington, DE, ³Nemours Biomedical Research, Wilmington, DE, ⁴Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Pediatric Rheumatology, Nemours/Thomas Jefferson University, Wilmington, DE
Background/Purpose: The goal of this project is the identification of informative synovial biomarkers to predict which children with oligoarticular juvenile idiopathic arthritis (JIA) will have…
Abstract Number: 141 • 2017 Pediatric Rheumatology Symposium
Expression of Siglec-10 on Synovial Fluid CD14dim Monocytes Was Decreased in Juvenile Idiopathic Arthritis Patients
Qianzi Zhao¹, Yang Liu², Pan Zheng² and Lawrence Jung³, ¹Rheumatology, Children's National Medical Center, Washington, DC, ²Cancer and Immunology Research Center, Children's National Medical Center, Washington, DC, ³Pediatric Rheumatology, Children's National Medical Center, Washington, DC
Background/Purpose: Monocytes plays a role in juvenile idiopathic arthritis (JIA). CD14dim monocytes have modulatory effects in innate and adaptive immune responses. Siglec-10, which is highly…
Abstract Number: 80 • 2017 Pediatric Rheumatology Symposium
Treatment of Blau Syndrome with Biologic Therapy: A Single Center Case Series of Seven Patients Over Two Decades
Jennifer Rammel¹, Patricia Rosillo¹, Tiphanie Vogel² and Marietta de Guzman³, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Department of Pediatrics, Division of Immunology, Allergy and Rheumatology and the Center for Human Immunology at Texas Children's Hospital., Baylor College of Medicine, Houston, TX, ³Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Blau syndrome is a rare autoinflammatory granulomatous disease that presents with fever, arthritis, dermatitis and uveitis. It results from mutations in NOD2, an intracellular…
Abstract Number: 89 • 2017 Pediatric Rheumatology Symposium
Abatacept as Adjunct Therapy for the Calcinosis of Juvenile Dermatomyositis: A Single-Center Experience
Marietta DeGuzman¹, Saimun Singla¹, Melissa Mizesko² and Anna Carmela Sagcal-Gironella³, ¹Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Division of Rheumatology, Driscoll Children's Hospital, Corpus Christi, TX, ³Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Juvenile dermatomyositis (JDMS) is an autoimmune inflammatory myopathy which primarily manifests with skin, muscle, and blood vessel involvement. Dystrophic calcification or calcinosis has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].